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essay provided by Reanne Frank (2008), and Derek
Exner and Jay Cohn (2008). Although Frank questions
the potential benefit of my critiques, I nonetheless find
her concerns and proposals to be quite persuasive. In
future work, I hope to be more attentive to these recom-
mendations, especially the suggestion to provide
detailed re-analysis whenever data are available. While
I would welcome the opportunity to discuss her essay in
greater detail, I feel the need to use the limited space
afforded to this rejoinder to address the more substantial
disagreements found in the commentary by Exner and
Cohn.
Exner and Cohn begin with a quotation from Roger
Bacon on the primacy of experimental science for
causal inference. I agree with this sentiment, and I
believe it to be consistent with my critique of the
post hoc analysis of the Studies of Left Ventricular
Dysfunction (SOLVD) data in Exner et al.’s article
‘‘Lesser response to angiotensin-converting-enzyme
inhibitor therapy in black as compared with white pa-
tients with left ventricular dysfunction’’ published in
the New England Journal of Medicine (Exner, Dries,* Tel.: þ1 9199667435; fax: þ1 9199662089.
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doi:10.1016/j.socscimed.2007.11.048Domanski, & Cohn, 2001) and which is the subject
of discussion. When one conditions effect estimates
on sub-groups that are not randomly assigned, the ben-
efits of randomization implied by Bacon are lost (Roth-
well, 2005). Exner and Cohn seem to recognize this
issue, since they insist that their paper was never in-
tended to be more than ‘‘hypothesis-generating’’. Yet
in many of their own subsequent citations of this paper,
this modesty is nowhere evident. For example, in the
2004 report of the A-HeFT trial results for which
Cohn is senior author (Taylor et al., 2004), the Exner
et al. paper is cited twice. The first citation appears af-
ter the statement ‘‘Retrospective analyses of . previ-
ous heart-failure trials strongly suggested that black
patients have a clinically significant response to a com-
bination of isosorbide dinitrate and hydralazine’’ (Tay-
lor et al., 2004, p. 2050). This is remarkable because
the Exner et al. paper did not investigate isosorbide di-
nitrate/hydralazine therapy at all. The second citation
references the statement ‘‘Retrospective analyses ac-
cording to race in. the Studies of Left Ventricular
Dysfunction have shown significant differences be-
tween blacks and whites in the response to pharmaco-
therapy for heart failure’’ (Taylor et al., 2004, p. 2054).
The statement is not only made without qualification
regarding the level of evidence, but also without spec-
ifying the one significant endpoint (hospitalization).
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insist that they did not gloss over the null finding for
the primary endpoint (mortality), but their own
citations to this study often refer broadly to lesser effi-
cacy of angiotensin converting enzyme (ACE) in-
hibition in blacks compared to whites (e.g., Cohn,
Loscalzo, & Franciosa, 2003). This is echoed in the
US Food and Drug Administration (FDA) Advisory
Committee Briefing Document prepared by NitroMed,
Inc. (2005) in support of the approval of BiDil with
race-specific labeling. The Exner et al. article is cited
twice in this document, once (p. 13) with the unquali-
fied statement that in the SOLVD trial, ‘‘black patients
responded less favorably to ACE inhibition than non-
black patients.’’ and once (p. 101) with the similarly
broad statement that ‘‘a re-analysis of the SOLVD trial
database has supported an attenuated effect of enalapril
in black patients.’’
Exner and Cohn (2008) then go on to defend the
matching strategy that was criticized in my essay.
From a paper I cited in my critique by Greenland and
Morgenstern, they extract a statement to support the
position that efficiency could be improved under some
conditions that they argue were plausibly met in their
study (Greenland & Morgenstern, 1990). This is a com-
plete misunderstanding of the cited paper. Greenland
and Morgenstern explain at the outset that they refer
to decisions about study design before the data have
been collected. They write:
‘‘Although cohort matching prevents confounding
by the matched variables, validity is not considered
an advantage of matched designs, since in an un-
matched study confounding by the covariates can
be removed by analytic methods. Thus, the chief
statistical advantage of matching is the potential
gain in efficiency of the design, i.e., the potential
gain in power or the reduction in variance produced
by matching, given a fixed maximum cost for the
study’’ (p. 151).
As Greenland and Morgenstern note, once the data
have already been collected, as they were in the case
of the SOLVD trial re-analyzed by Exner, Dries, et al.
(2001), then conditioning on the covariates can be ac-
complished readily with statistical adjustment. In fact,
there could be an advantage to the non-parametric con-
trol achieved by matching, since it avoids reliance on
a specific model form (Ho, Imai, King, & Stuart,
2007), but this would be consequential if there were im-
portant heterogeneity of the treatment effect by the
matched covariates, a situation that Exner et al. do not
consider.Exner and Cohn next take issue with my assertion
that groups with higher baseline risk will in general
have more modest response to treatment on the ratio
scale. I provided an explanation of this phenomenon us-
ing a counterfactual model, and they responded by cit-
ing an essay which argued that counterfactual models
are not helpful. Regardless of the attractiveness of the
explanatory model, however, the phenomenon itself is
not disputed by Dawid (2002) or any other author that
I am aware of, and has been noted widely without refer-
ence to the counterfactual explanation that I provided
(e.g., Rothwell, 2005). Indeed, Exner and Cohn
(2008) support the same distinction when they note
that ‘‘.patients with left ventricular systolic dysfunc-
tion and a higher baseline risk derive greater benefit
from therapeutic interventions, in terms of absolute ben-
efit.’’(my emphasis).
Finally, Exner and Cohn (2008) state that the 2001
article ‘‘.never attempted to identify genetic or envi-
ronmental factors that might contribute to our
observations.’’ These authors published a response to
letters to the editor several months after the original
paper appeared, however, and the second sentence of
this response states ‘‘Differences in therapeutic re-
sponse probably relate, in part, to polymorphisms in
drug receptors, drug-metabolizing enzymes, or other
factors’’ (Exner, Domanski, & Cohn, 2001, p. 767).
Similar statements also appear in other articles on
which Cohn is an author. For example, citing the Exner
et al. article, a 2002 publication states: ‘‘Evidence sug-
gests impaired vasoreactivity of African Americans,
and studies suggest that nitric oxide (NO)-mediated
vasodilation is impaired in the microvasculature of
African-American patients’’ (Franciosa et al., 2002,
p. 129).
I accept Frank’s final point, which is that researchers
such as Exner and Cohn are no doubt dedicated scien-
tists who are committed to uncovering the causes of
racial disparities. Her recommendation is therefore to
avoid depreciatory attacks and to focus instead on the
evidence conveyed in the published literature. We all
seem to be in agreement that many authors have cited
the Exner et al. New England Journal of Medicine paper
(2001) injudiciously, attributing to that paper conclu-
sions that the SOLVD data do not logically support.
As I have noted in this rejoinder, however, some of these
questionable interpretations of the paper are in fact
authored by Exner and Cohn themselves. Despite
Frank’s pessimism concerning the potential value of
this dialogue, I trust that in future work, Exner and
Cohn’s publications will reflect more of the cautious
skepticism expressed in their commentary here.
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